| Cat.No. | Name | Information |
|---|---|---|
| M1641 | Quizartinib (AC220) | Quizartinib (AC220) is a uniquely potent and selective FLT3 inhibitor. |
| M7527 | Gilteritinib | Gilteritinib is a potent FLT3/AXL inhibitor with IC50 of 0.29 nM/0.73 nM, respectively. |
| M29485 | Tuspetinib | Tuspetinib (HM43239) is an orally active and selective FLT3 inhibitor with IC50s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. Tuspetinib inhibits the kinase activity of FLT3 as a reversible type I inhibitor and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib inhibits the proliferation and induces the apoptosis of leukemic cells. |
| M29479 | FLT3/ITD-IN-4 | FLT3/ITD-IN-4 (Compound 16) is a selective FMS-like tyrosine kinase 3 internal tandem duplications (FLT3-ITD) inhibitor with an IC50 of 2.3 nM. FLT3/ITD-IN-4 can be used for acute myeloid leukemia research. |
| M29420 | HP1328 | HP1328 is a potent inhibitor of FLT3 receptor tyrosine kinase (FLT3/ITD mutation). HP1328 is a benzoimidazole scaffold-based compound. HP1328 significantly reduces the leukemia burden and prolongs the survival of mice with FLT3/ITD leukemia. |
| M28236 | OTS447 | OTS447 is a potent FLT3 inhibitor with an IC50 of 21 nM (WO2012016082A1, compound 335). |
| M28176 | BPR1J-097 | BPR1J-097 is a novel potent FLT3 inhibitor with an IC50 of 11 nM. |
| M20679 | SKLB4771 (FLT3-IN-1) | SKLB4771 is a potent and selective inhibitor of human receptor-type tyrosine-protein kinase FLT3 with IC50 of 10 nM. |
| M20359 | WAY-304191 | WAY-304191 is a CXCR3 antagonist. |
| M20307 | WAY-663387 | WAY-663387 is a FLT3 kinase inhibitor. |
| M20061 | WAY-297342 | WAY-297342 is a inhibitor of Influenza Virus Polymerase |
| M14902 | UNC2025 hydrochloride | UNC2025 hydrochloride is a potent, ATP-competitive, and highly orally active Mer/Flt3 inhibitor with IC50 values of 0.74 nM and 0.8 nM, respectively. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
